Evaluation of the effects of rice bran powder administration on cardiovascular risk factors in adult patients with metabolic syndrome

Evaluation of the effects of rice bran powder administration on cardiovascular risk factors in adult patients with metabolic syndrome: A Randomized Controlled Open Label Trial

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20180205038626N11

Enrollment

Registered

2021-11-27

Start date

2021-11-22

Completion date

Unknown

Last updated

2021-11-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metabolic syndrome. Metabolic syndrome

Interventions

Intervention 1: Intervention group: Patients with metabolic syndrome will be given 15 grams of rice bran equivalent to 1 tablespoon of Giltaz daily for eight weeks. Intervention 2: Control group: A st

Eligibility

Sex/Gender

All

Age

20 Years to 70 Years

Inclusion criteria

Inclusion criteria: Patients with an age range of 20 to 70 years Patients with metabolic syndrome Do not use vitamin and mineral supplements, antioxidants, fiber supplements, omega 3 No history of kidney disease, kidney stones, gastrointestinal diseases, gallstones, and autoimmune diseases No current consumption of alcohol

Exclusion criteria

Exclusion criteria: Changes in the patient's treatment plan during the study Changing the type of effective drugs used factors studied Reluctance to continue the study or to cause any dissatisfaction with the taste of the powder or to participate in the study

Design outcomes

Primary

Measure	Time frame
Serum lipid profile levels (triglycerides, total cholesterol, LDL-C and HDL-C). Timepoint: At the beginning of the study and 8 weeks later. Method of measurement: BT2000 device.;Serum levels of Apo A1 and Apo B100. Timepoint: At the beginning of the study and 8 weeks later. Method of measurement: Nephrometric device.;Fasting blood sugar. Timepoint: At the beginning of the study and 8 weeks later. Method of measurement: BT2000 device.;CRP. Timepoint: At the beginning of the study and 8 weeks later. Method of measurement: BT2000 device.;D-dimer. Timepoint: At the beginning of the study and 8 weeks later. Method of measurement: ELISA device.	—

Measure

Time frame

Serum lipid profile levels (triglycerides, total cholesterol, LDL-C and HDL-C). Timepoint: At the beginning of the study and 8 weeks later. Method of measurement: BT2000 device.;Serum levels of Apo A1 and Apo B100. Timepoint: At the beginning of the study and 8 weeks later. Method of measurement: Nephrometric device.;Fasting blood sugar. Timepoint: At the beginning of the study and 8 weeks later. Method of measurement: BT2000 device.;CRP. Timepoint: At the beginning of the study and 8 weeks later. Method of measurement: BT2000 device.;D-dimer. Timepoint: At the beginning of the study and 8 weeks later. Method of measurement: ELISA device.

—

Secondary

Measure	Time frame
Mean systolic and diastolic blood pressure. Timepoint: At the beginning of the study and 8 weeks later. Method of measurement: Pressure indicator.;Body mass index. Timepoint: At the beginning of the study and 8 weeks later. Method of measurement: Centimeter and scales.;Waist. Timepoint: At the beginning of the study and 8 weeks later. Method of measurement: Centimeter.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactZahra ahmadnia

Rasht University of Medical Sciences

zahmadnia@gums.ac.ir+98 13 3361 8177

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026